Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases

Dermatol Ther. 2021 Jul;34(4):e15007. doi: 10.1111/dth.15007. Epub 2021 Jun 2.

Authors

Ecem Bostan¹, Duygu Gulseren¹, Basak Yalici-Armagan¹, Sibel Dogan¹, Deniz Ates-Ozdemir², Ozay Gokoz², Umut Kalyoncu³, Nilgün Atakan¹

Affiliations

¹ Department of Dermatology and Venereology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
² Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
³ Department of Rheumatology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

PMID: 34046982
DOI: 10.1111/dth.15007

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Antirheumatic Agents*
Certolizumab Pegol / adverse effects
Humans
Treatment Outcome
Tumor Necrosis Factor-alpha
Vasculitis*

Substances

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Tumor Necrosis Factor-alpha
secukinumab
Certolizumab Pegol